TELA Bio, Inc. 8-K

What Happened

• On April 29, 2026 (filed 8-K April 30, 2026), TELA Bio announced preliminary, unaudited revenue of approximately $19.0 million for the quarter ended March 31, 2026. Management prepared this estimate; quarter-end close is not complete and KPMG LLP has not audited or reviewed this figure. Final results will be reported in the Company’s Form 10-Q for the quarter and may differ materially.
• The Company also disclosed board changes: Doug Evans, Chair of the Board, will not stand for re-election and will retire from the Board effective immediately following the 2026 Annual Meeting (June 9, 2026). The Board nominated Joseph Capper for election as a Class I director and, if elected, to serve as Chair. Three current directors (Kurt Azarbarzin, Vince Burgess and Federica O’Brien) also tendered resignations effective after the 2026 Annual Meeting. The Board appointed Guido Neels (Class II), Guy Nohra (Class III) and Paul Thomas (Class III) to take office immediately following the Annual Meeting.

Key Details

• Preliminary revenue: approximately $19.0 million for quarter ended March 31, 2026; unaudited and subject to change pending close procedures and Form 10-Q disclosure.
• Director changes effective after 2026 Annual Meeting (June 9, 2026): Doug Evans retiring; Joseph Capper nominated as director and prospective Chair; Neels, Nohra and Thomas appointed as incoming directors.
• Equity and compensation for incoming directors and Capper: initial award to be granted immediately after the Annual Meeting consisting of (i) option to purchase 17,550 shares (vests monthly over 36 months) and (ii) 11,925 RSUs (vest in three equal annual installments); cash board compensation per policy.
• Departing directors will have post-termination option exercise periods extended to the earlier of (i) 12 months after the Annual Meeting or (ii) the options’ expiration dates. Capper is not expected to be independent under Nasdaq rules; the three appointed directors are deemed independent.

Why It Matters

• Earnings/financials: The $19.0M preliminary revenue figure gives an early view of quarterly performance but is unaudited and incomplete; investors should wait for the Form 10-Q for audited, GAAP-compliant results.
• Corporate governance: Leadership changes—particularly the retirement of the Chair and the nomination of an industry veteran (Joseph Capper) as Chair—could affect strategic direction and investor confidence. The Board’s addition of three experienced life-science/MedTech executives may influence oversight and commercial strategy.
• Compensation and dilution: Initial equity grants and options for incoming directors and Capper create potential future dilution; investors should monitor total share-based compensation disclosures in upcoming filings.